SmartHealth Dx Experienced Leadership With Proven Success In Development And Commercialization
Mitch LevineChief Executive Officer & Chairman of the Board Mitch Levine is a strategic-minded Chief Financial Officer, corporate finance innovator, and investment industry leader who has orchestrated mission-critical financial strategies to enhance corporate value and strengthen operating performance for both public and private companies in the life sciences industry. Read More
From 2017 to 2022, Mr. Levine was the Chief Financial Officer of Oncocyte (OCX: NasdaqGM) a molecular diagnostic company, where he oversaw corporate growth from eight employees to more than 120; conducted 10 capital raises bringing the company to fully-funded status; built the shareholder base from one institutional investor to more than 50; negotiated and integrated three acquisitions; and secured the largest licensing deal in company history with one of the largest and fastest-growing diagnostic laboratories in China. From 2000 to 2017, Mr. Levine was Founder and Managing Member of Enable Capital Management, LLC, whose underlying investment vehicle, Enable Growth Partners, LP, was one of the largest funds providing growth capital to small and mid-sized public and private companies. Prior to Enable Capital Management, Mr. Levine was a Founding Member of the Shemano Group, a San Francisco-based investment bank focused on the capital needs of technology and life science companies where Mr. Levine was widely recognized for originating and developing one of the largest alternative financing markets in the US, generating more than $100 billion of financings annually.
Matthew NunezPresident & Chief Business Officer Matthew Nuñez has served as Chief Executive Officer of SmartHealth Dx since 2019. Mr. Nuñez, an entrepreneur, has built businesses in diagnostic biomarker discovery, bioinformatics, advanced analytics, and precision medicine. Read More
Mr. Nuñez’ successes include Emerald Logic, which conducted development and discovery projects in the pharmaceutical industry including Amgen, Allergan, and Novartis; BluePrint Bio, a developer of proprietary biomarker technology for the personalized medicine market; and BluePen Biomarkers, a joint venture between BluePrint Bio, Emerald Logic and the University of Pennsylvania. Mr. Nuñez also co-founded Liquid Biosciences, a leader in AI technology for diagnostic, predictive, and therapeutic applications, a result of the merger of BluePrint Bio and Emerald Logic.
Douglas Harrington, MDFounder Dr. Douglas Harrington has over 25 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. Dr. Harrington began his career as a member of Dr. Jack Copeland’s first heart transplant team in Arizona in 1979. He co-founded one of the US’s first clinical molecular biology laboratories with the Nebraska Lymphoma Study Group headed by Dr. Jim Armitage. Read More
As former President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology, cytogenetic, and anatomic pathology offerings. Dr. Harrington has developed patents for an automated method for image analysis of residual cancer protein, a patent covering catalytic heavy metal extraction, and a patent pending on biomarker assay for diagnosis and classification of cardiac disease. He has been involved as a director or founder of multiple startup companies – from devices to molecular genetics focusing on immunology, cancer, and cardiology. He has taken several new molecular technologies through state and federal regulatory approval. Throughout his career, Dr. Harrington has remained a Clinical Professor of Pathology at the USC Keck School of medicine. Dr. Harrington has authored and published numerous peer-reviewed papers and is a renowned lecturer in preventive medicine. Dr. Harrington received his BA in molecular biology and MD from the University of Colorado at Boulder and is board certified in hematology, anatomic and clinical pathology.
Larry DenticeChief Commercial Officer & Director Larry Dentice is a highly regarded senior healthcare executive and a 35-year veteran of the diagnostics imaging field with proven expertise in engineering, service, manufacturing, marketing, sales, and business operations for several Fortune 500 companies Read More
including Toshiba America Medical Systems, Philips Healthcare, Canon Medical Systems, and GE Healthcare. As Chief Commercial Officer, Mr. Dentice oversees the commercialization and distribution of the entire SmartHealth Dx diagnostic and imaging tests.
Susie LuChief Operating Officer Susie Lu brings years of experience to her role as Chief Operating Officer. She has a proven record of running large-scale, highly complex laboratory operations by providing visionary and operational direction for developing and implementing laboratory outreach programs in institutions. Read More
Some of Ms. Lu’s successes include Columbia HCA Hospitals, where she was an Executive Director; UCSF Health/Mount Zion Hospital; Stanford Health System/Lucile Packard Children’s Hospital; UCLA Health System/Santa Monica Hospital, where she served as Vice President of Operations; and Zhe Jiang University Medical Center in China, where she is the Chief Consultant (since 2014).
Ken BrightChief Financial Officer Ken Bright has 15 years of senior management experience in the pharmaceuticals, diagnostics, and life science tools industries as a corporate controller, CFO and advisor. Read More
Prior to joining SmartHealth Dx, Mr. Bright was the Corporate Controller for DNAtrix, a privately held pharmaceutical company, Guardion Health Sciences (ticker: GHSI), a publicly traded ocular nutraceuticals/diagnostics company, and Aeolus Pharmaceuticals (ticker: AOLS) a publicly traded pharmaceuticals company. At each company, he handled all aspects of accounting and financial reporting. Mr. Bright has also served as a Chief Financial Officer and advisor to a cancer diagnostics startup and a life science tools startup. Mr. Bright received a BA in Business Economics from University of California Santa Barbara and holds an inactive CPA license in the state of California.
Paul DenticePresident Imaging Technologies Paul Dentice brings tremendous experience to his new role as part of the SmartHealth Dx executive team. Mr. Dentice has over 20 years of experience in diagnostic imaging, sales, technical, and leadership roles. Read More
He has succeeded in his roles with several healthcare industry leaders, including Siemens and Philips Healthcare. Throughout Mr. Dentice’s career, he has maintained an impressive track record for developing key relationships with market leaders and academics, exceeding quotas, and growing market share with his team.